Related Experiment Video

Updated: Mar 21, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

900

[Role of PDGF/PDGFR Pathway in Essential Thrombocythemia and Its Action Mechanism]

Li-Xia Zhou1, En-Yu Liang1, Jie-Yu Ye2

  • 1Department of Hematology, South Hospital of Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|May 7, 2016
PubMed

Insights

Elevated platelet-derived growth factor-BB (PDGF-BB) and its receptor PDGFR-β are linked to essential thrombocythemia (ET). Inhibiting PDGFR with imatinib may offer a new therapeutic strategy for ET by blocking megakaryocyte overproduction.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by excessive platelet production.
  • The role of platelet-derived growth factor (PDGF) and its receptor (PDGFR) in ET pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the expression of PDGF-BB and PDGFR-β in ET patients.
  • To explore the potential of PDGFR as a therapeutic target in ET by examining the effects of imatinib on megakaryopoiesis.

Main Methods:

  • ELISA was used to measure PDGF-BB levels in bone marrow.
  • Flow cytometry detected PDGFR-β expression on bone marrow cells.
  • Western blot and flow cytometry analyzed PDGF-BB's effect on JAK2/STAT3 and PI3K/AKT pathways.
  • Imatinib's impact on megakaryopoiesis was assessed.

Main Results:

  • ET patients exhibited significantly higher PDGF-BB and PDGFR-β expression in bone marrow compared to controls.
  • PDGF-BB activated JAK2/STAT3 and PI3K/AKT pathways in megakaryocytes.
  • Imatinib successfully blocked PDGF-BB-induced activation of these pathways and inhibited megakaryocyte proliferation.

Conclusions:

  • Elevated PDGF-BB and PDGFR-β are implicated in ET pathogenesis.
  • The mechanism involves PDGF-BB activating PDGFR, subsequently activating JAK2/STAT3 and PI3K/AKT pathways, leading to increased megakaryopoiesis.
  • Imatinib demonstrates potential as a therapeutic agent for ET by targeting PDGFR.
Abstract

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Concept Videos

Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K